Energy Metabolism REFERENCES

Figure caption    Figure 1 Cartoon of the mechanism of the proposed hypothesis(A wide range of insults can result in a patient reducing activity over a substantial period of time (weeks or months). This leads to reduced RAS and sympathetic activity, and hence to an decrease in mitochondrial number and increase in efficiency which leads to an inability to sustain high power output levels, and hence exertional pain on even mild exercise).

References

1 Wessely S, Hotopf M, Sharpe M. Chronic Fatigue and its Symptoms. Oxford UK: Oxford University Press; 1998. 2 Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006;387:346-55. 3 Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, Edwards RH, Hawton KE, Lambert HP, Lane RJ. A report - chronic fatigue syndrome: guidelines for research. J. Royal Society of Medicine 1991;84(2):118-21. 4 Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins JG, Komaroff A. The chronic fatigue syndrome. Annals of Internal Medicine 1994;121(12):853-959. 5 Center for Disease Control, Chronic Fatigue Syndrome http://www.cdc.gov/ncidod/diseases/cfs/ (produced by Center for Disease Control, accessed 30th November 2005). 6 Stokes M, Cooper R, Edwards RH. Normal strength and fatiguability in patients with effort syndrome. British Medical Journal 1988;297:1014-8. 7 Lloyd A, Gandevia S, Hale J. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with chronic fatigue syn- drome. Brain 1991;114:85-98. 8 Sargent C, Scroop GC, Nemeth PM, Burnet RB, Buckley FD. Maximal oxygen uptake and lactate metabolism are normal in chronic fatigue syndrome. Med. Sci. Sports Exercise. 2002;34(1):51-6. 9 J Lane R, Woodrow D, Archard LC. Lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatry. 1994;57:662-3. 10 Lane RJM, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC. Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome. J. Neurol. Neurosurg. Psychiatry. 1998;64:362-7. 11 Timmers HJ, Wieling W, Soetekouw PM, Bleijenberg G, van der Meer JW, lenders JW. Hemodynamic and neuromumo- ural responses to head-up tilt in patients with chronic fatigue syndrome. Clin. Auton. Res. 2002;12(4):273-80. 12 Ferrari R, Cicchitelli G, Merli E, Andreadou I, Guardigli G. Metabolic modulation and optimization of energy consump- tion in heart failure. Med. Clin. North America 2003;87(2):493-507. 13 Ventura-Clapier R, De Sousa E, Veksler V. Metabolic myopathy in heart failure. News Physiol. Science. 2002;17: 191-6. 14 Deluca J, Johnson SK, Ellis SP, Natelson BH. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psyciatric disease. J. Neurol. Neuro- surg. Psychiatry 1997;62:151-5. 15 Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB, Prevalence Chronic fatigue in primary care, characteristics patient. and outcome. Journal of the American Medical Association 1988;260(7):929-34. 16 Wilson A, Hickie I, Lloyd A, Hadzi-Pavlovic D, Boughton C, Dwyre J, Wakefield D. Longitudinal study of outcome of chronic fatigue syndrome. British Medical Journal 1994;308: 756-9. 17 Whiting P, Bagnall A-M, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and manage- ment of chronic fatigue syndrome. Journal of the American Medical Association 2001;286(11):1360-8. 18 Lloyd A, Pender H. The economic impact of chronic fatigue syndrome. Med. J. Aust. 1992;157(9):599-601. 19 Gunn WJ, Connell DB, Randall B. Epidemiology of chronic fatigue syndrome: the Centres for Disease COntrol study. Ciba Foundation Symposium 1993;173:83-93. 20 Lawrie SM, Pelosi AJ. Chronic fatigue syndrome in the community Prevalence and associations. British Journal of Psychiatry 1995;166:793-7. 21 Jason LA, Richman JA, Rademaker AW, Jordan KM, Pliophys AV, Taylor RR, McCready W, Huang CF, Pliophys S. A community-based study of chronic fatigue syndrome. Archives of Internal Medicine 1999;159(18):2129-37. 22 Reyes M, Nisenbaum R, Hoaglin DC, Unger ER, Emmons C, Randall B, Stewart JA, Abbey S, Jones JF, Gantz N, MInden S, Reeves WC. Prevalence and incidence of Chronic Fatigue Syndrome in Wichita, Kansas. Archives of Internal Medicine 2003;163:1530-6. 23 Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Annals of Internal Medicine 1995;123(2):81-8. 24 Reid S, Chalder T, Cleare A, Hotopf M. Chronic fatigue syndrome. British Medical Journal 2000;320(7230):292-6. 25 C. Jackson, Chronic Fatigue Syndrome http://www.pa- tient.co.uk/showdoc/40000806/ (produced by EMIS, accessed 25th Jan 2006). 26 Evengard B, Schacterle RS, Komaroff AL. Chronic fatigue syndrome: new insights and old ignorance. Journal of Internal Medicine 1999;246:455-69. 27 Borish L, Schmaling K, DiClementi JD, Streib J, NegriJ, Jones JF. Chronic fatigue syndrome: identification of distinct subgroups on basis of allergy and psychological variables. Journal of Allergy and Clinical Immunology 1998;102(2):222-30.28 Nieman DC. Is infection risk linked to exercise workload? Medicine and Science in Sports and Exercise 2000;32(7): S406-11. 29 Budgett R. ABC of sports medicine. The overtraining syndrome. British Medical Journal 1994;309:465-8. 30 Budgett R, Newsholme E, Lehmann M, Sharp C, Jones D, Jones T, Peto T, Collins D, Nerurkar R, White P. Redefining the overtraining syndrome as the unexplained underper- formance syndrome. British Journal of Sports Medicine 2000;34:67-8. 31 Clauw DJ, Chrousos GP. Chronic pain and fatigue syn- dromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomod- ulation 1997;4(3):134-53. 32 Bagnall AM, Whiting P, Richardson R, Sowden AJ. Interven- tions for the treatment and management of chronic fatigue syndrome myalgic encephalomyelitis. Qual. Saf. Health Care 2002;11:284-8. 33 Reid S, Chalder T, Cleare A, Hotopf M, Wessely S. Chronic fatigue syndrome. Clinical Evidence 2005;15:1-3. 34 Straus SE. Pharmacotherapy of chronic fatigue syndrome. Journal of the American Medical Association 2004;292(10): 1234-5. 35 Wessely S, David A, Butler S, Chalder T. Management of chronic (post-viral) fatugue syndrome. Journal of the Royal College of General Practitioners 1989;39(318): 26-9. 36 Wessely S, Powell R. Fatigue syndromes: a comparision of chronic 'postviral' fatigue with neuromuscular and affec- tive disorders. J. Neurol. Neurosurg. Psychiatry 1989;52: 940-8. 37 Natelson BH. Chronic Fatigue Syndrome. Journal of the American Medical Association. 2003;285(20):2557-9. 38 Skapinakis P, Lewis G, Meltzer H. Clarifying the relationship betweenunexplained chronic fatigue and psychiatric mor- bidity: results from a community survey in Great Britain. American Journal of Psychiatry 2000;157:1492-8. 39 Lane TJ, Manu P, Matthews DA. Depression and somatiza- tion in the chronic fatigue syndrome. American Journal of Medicine 1991;91(4):335-44. 40 Fuhrer R, Wessely S. The epidemiology of fatugue and depression: a French primary-care study. Psychological Medicine 1995;25(5):895-905. 41 Taylor RR, Jason LA, Jahn SC. Chronic fatigue and sociodemographic characteristics as predictors of psychi- atric disorders in a community-based sample. Psychoso- matic medicine 2003;65:896-901. 42 Vercoulen JH, Swanink CM, Zitman FG, Vreden SG, Hoofs SG, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Randomised, double-blind, placebo-controlled study of flu- oxetine in chronic fatigue syndrome. Lancet 1996;347(9005): 858-61. 43 Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA. Randomised double- blind placebo-cntrolled treatment trial of fluoxetine andgraded exercise for chronic fatigue syndrome. British Journal of Psychiatry 1998;172:485-90. 44 Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Wood- ward C, Howe I, Ali T. Effect of galantamine hydrochloride in chronic fatigue syndrome: a randomized controlled trial. Journal of the American Medical Association 2004;292(10): 1195-204. 45 Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. Journal of Clinical Immunology 1999;19(5):314-6. 46 Cannon JG, Angel JB, Adad LW, O'Grady J, Lundgrem N, Fagioli L, Komaroff AL. Hormonal influences on stress-induced neutrophil mobilixation in health and chronic fatigue syn- drome. Journal of Clinical Immunology 1998;18(4):291-8. 47 Lloyd A, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D. Immunologic and psychologicl therapy for patients with chronic fatigue syndrome: a double-blind placebo-controlled trial. American Journal of Medicine 1993;94(2):197-203. 48 Steinberg P, McNutt BE, Marshall P, Schenk C, Lurie N, Pheley A, Petersen PK. Double blind placebo-controlled study of the efficacy oforal terfenadine in the treatment of chronic fatigue syndrome. J. Allergy and clinical immunol- ogy 1996;97(1):119-26. 49 Rasmussen AK, Andersen V, Nielsen H, Wiik A. Chronic fatigue syndrome - a defined unity? Ugeskr Laeger 1995;157(6): 756-7. 50 Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, Chrousos GP, Gold PW. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. Journal of Clinical Endocrinology and Metabolism 1991;73:1224-34. 51 Adler GK, Manfredsdottir VF, Rackow RM. Hypothalamic- pituitary-adrenal axis function in fibromyalgia and chronic fatigue syndrome. The Endocrinologist 2002;12(6):513-24. 52 Kavelaars A, Kuis W, Knook L, Sinnema G, Heijnen CJ. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 2000;85: 692-6. 53 Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic- pituitary-adrenal axis in chronic fatigue syndrome anor- exia nervosa and major depression. Medical Hypotheses 2005;65(2):287-95. 54 Cleare A. The neuroendocrinology of chronic fatigue syndrome. Endocrinology Reviews 2003;24:236-52. 55 Shin JI, Lee JS. Can chronic fatigue symptoms associated with nutcracker phenomenon be treated with aspirin? Medical Hypotheses 2007;69(3):704-5. 56 Gharibzadeh S, Hoseini SS. Is there any relation between moldy building exposure and chronic fatigue syndrome? Medical Hypotheses 2006;66(6):1243-4. 57 Miller R. Thimerosal micromercurialism and chronic fatigue syndrome. Medical Hypotheses. 2005;64(5):1063-4. 58 Buskila D, Press J. Neuroendocrine mechanisms in fibromy-algia - chronic fatigue. Best practice and research clinical rheumatology. 2001;15(5):747-58. 59 Janal MN, Ciccone DS, Natelson BH. Sub-typing CFS patients on the basis of 'minor' symptoms. Biological Psychiatry 2006;73(2):124-31. 60 Ciccone DS, Natelson BH. Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis. Psychosomatic medicine 2003;65:268-75. 61 McCully KK, Natelson BH, Iotti S, Sisto S. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 1996;19(5):621-5. 62 McCully KK, Natelson BH. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clinical Science 1999;97:603-8. 63 McCully KK, Smith S, Rajaei S, Leigh Jr JS, Natelson BH. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J. Applied Physiology 2003;96:871-8. 64 Behan WM, More IA, Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathologica 1991;83(1):61-5. 65 Lieberman J, Bell DS. Serum angiotensin-converting enzyme as a marker for the chronic fatigue-immune dysfunction syndrome: a comparison to serum angioten- sin-converting enzyme in sarcoidosis. American Journal of Medicine 1993;95(4):407-12. 66 Vladutiu GD, Natelson BH. Association of medically unex- plained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans. Muscle Nerve 2004;30(1):38-43. 67 Bakheit AM, Behan PO, Watson WS, Morton JJ. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol. Scand. 1993;87(3):234-8. 68 Cinti S, Cancello R, Zingaretta MC, Ceresi E, de Matteis R, Giordano A, Himms-Hagen J, Ricquier D. CL316243 and cold stress induce heterogenous expression of UCP-1 mRNA and protein in rodent brown adipocytes. Journal of histochem- istry and cytochemistry 2002;50:21-32. 69 Hansen JB,Jorgensen C, Petersen RK, Hallenborg P, de MatteisR, Boye HA, Petrovic N, Enerback S, Nedergaard j, Cinti S, te Riele H, Kristiansen K. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. Proc. Nat. Acad. Sci. 2004;101(12):4112-7. 70 Nagase I, Yoshida T, Kumamoto K, Umekawa T, Sakane N, Nikami H, Kawada T, Saito M. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta-3 adrenergic agonist. J. Clin. Invest. 1996;97(12):2898-904. 71 Jimenez M, Barbatelli G, Allevi R, Cinti S, Seydoux J, Giacobino J-P, Muzzin P, Preitner F. Beta-3-adrenoceptor knockout in C57BL/6J mice depresses the occurence of brown adipocytes in white fat. European Journal of Biochemistry 2003;270:699-705.72 Wu H, Kanatous SB, Thurmond FA, Gallardo T, Isotani E, Bassel-Duby R, Williams RS. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002;296 (5566):349-52. 73 Vinson GP, HMehta J, Evans S, Matthews S, Puddefoot JR, Saridogan E, Holt WV, Djahanbakhch O. Angiotensin II stim- ulates sperm motility. Regulatory Peptides 1996;67(2):131-5. 74 Ball BA, Gravance CG, Wessel MT, Sabeur K. Activity of angiotensin-converting enzyme (ACE) in reproductive tis- sues of the stallion and effects of angiotensin II on sperm motility. Theriogenology 2003;59(3 ­4):901-14. 75 Montgomery H, Marshall R, Hemingway H, Myserson S, Clarkson P, Dollery C, Hayward M, Holliman DE, Jubb M, Thomas EL, Brynes AE, Saeed N, Barnard M, Bell JD, Prasad K, Rayson M, Talmud PJ, Humphries S. Human gene for physical performance. Nature 1998;393:221-2. 76 Alvarez R, Terrados N, Ortolana R, Iglesias-Cubero G, Reguero JR, Batalla A, Cortina A, Fernandez-Garcia B, Rodriguez C, Socorro B, Alvarez V, Coto E. Genetic variation in the renin- angiotensin system and athletic performance. European Journal of Applied Physiology 2000;82(1 ­2):117-20. 77 Jones A, Montgomery H, Woods DR. Human performance: a role for the ACE genotype? Sports Science Review 2002;30(4): 184-90. 78 Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJF. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symp- toms. Free radical biology and medicine 2005;39:584-9. 79 de Grey AD. A proposed refinement of the mitochondrial free radical theory of ageing. Bioessays 1997;19(2):161-6. 80 de Grey AD. A mechanism proposed to explain the rise in oxidative stress during aging. Journal of Anti-ageing med- icine 1998;1(1):53-66. 81 Newsholme E, Stark C. Regulation in metabolism. Winches- ter UK: Wiley; 1973. 82 Naschitz JE, Dreyfuss D, Yeshurun D, Rosner I. Midodrine treatment for chronic fatugue syndrome. Postgraduate Medicine 2004;80:230-2. 83 Walker et alnuclear Multiplex polymerase chain reaction for simultaneous quantitation of human. mitochindrial and male Y-chromosome DNA: application in human identification. Analytical Biochemistry 2005;337(1): 89-97. 84 Alonso et al. Real-time PCR designs to estimate nuclear and mitochondrial DNA copy number in forensic and ancient DNA studies. Forensic Science International 2004;139(2-3): 141-9. 85 Emaus RK et al. Biochim. Biophys Acta 1986;850(3):436-48. 86 Feeney et al. Journal of Neurosciences 2003;125( 1-2): 13-25. 87 Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994;49:771-4. 88 Lipworth BJ, Newnham DM, Clark RA, Dhillon DP,Winter JH, McDevitt DG. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995;50: 54-61. 89 Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lotvall J. Relative systemic dose potency and tolerabil- ity of inhaled formoterol and salbutamol in healthy subjects and asthmatics. European Journal of CLinical Pharmacology 2000;56(5):363-70. -------- (c) 2008 Elsevier / ScienceDirect B.V.